Key facts
- This page summarizes Cormorant Asset Management, LP's Form 4 filing for Ambrx Biopharma Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Sep 2023, 16:49.
Cormorant Asset Management, LP - 15 Sep 2023 Form 4 Insider Report for Ambrx Biopharma Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 15 Sep 2023
- Net transaction value
- +$19,625,601
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2023, 16:49:06 UTC
- Prior SEC filing
- 24 Jul 2023
- Next SEC filing
- 25 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cormorant Asset Management, LP filed Form 4 for Ambrx Biopharma Inc. on 19 Sep 2023.
Change
- Previous filing in this sequence was filed on 24 Jul 2023.
- Current net transaction value: +$19,625,601.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMAM
transaction
Ordinary Shares
Purchase
- Transaction value
- $12,680,677
- Shares
- +1,401,505
- Change %
- +2.1%
- Price
- $9.05
- Shares after
- 68,714,590
- Date
- 15 Sep 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
AMAM
transaction
Ordinary Shares
Purchase
- Transaction value
- $6,944,924
- Shares
- +751,233
- Change %
- +1.1%
- Price
- $9.24
- Shares after
- 69,465,823
- Date
- 18 Sep 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $9.00 to $9.30 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund (as defined below).
Footnote F2
Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Footnote F3
Represents (i) 51,172,870 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.
Footnote F4
Represents (i) 51,924,103 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.